 |
|
Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary AngiographyA Randomized Controlled Trial
Marta Ebbing, MD;
Øyvind Bleie, MD, PhD;
Per Magne Ueland, MD, PhD;
Jan Erik Nordrehaug, MD, PhD;
Dennis W. Nilsen, MD, PhD;
Stein Emil Vollset, MD, DrPH;
Helga Refsum, MD, PhD;
Eva Kristine Ringdal Pedersen, MD;
Ottar Nygård, MD, PhD
JAMA. 2008;300(7):795-804.
Context Observational studies have reported associations between circulating total homocysteine concentration and risk of cardiovascular disease. Oral administration of folic acid and vitamin B12 can lower plasma total homocysteine levels.
Objective To assess the effect of treatment with folic acid and vitamin B12 and the effect of treatment with vitamin B6 as secondary prevention in patients with coronary artery disease or aortic valve stenosis.
Design, Setting, and Participants Randomized, double-blind controlled trial conducted in the 2 university hospitals in western Norway in 1999-2006. A total of 3096 adult participants undergoing coronary angiography (20.5% female; mean age, 61.7 years) were randomized. At baseline, 59.3% had double- or triple-vessel disease, 83.7% had stable angina pectoris, and 14.9% had acute coronary syndromes.
Interventions Using a 2 x 2 factorial design, participants were randomly assigned to 1 of 4 groups receiving daily oral treatment with folic acid, 0.8 mg, plus vitamin B12, 0.4 mg, plus vitamin B6, 40 mg (n = 772); folic acid plus vitamin B12 (n = 772); vitamin B6 alone (n = 772); or placebo (n = 780).
Main Outcome Measures The primary end point was a composite of all-cause death, nonfatal acute myocardial infarction, acute hospitalization for unstable angina pectoris, and nonfatal thromboembolic stroke.
Results Mean plasma total homocysteine concentration was reduced by 30% after 1 year of treatment in the groups receiving folic acid and vitamin B12. The trial was terminated early because of concern among participants due to preliminary results from a contemporaneous Norwegian trial suggesting adverse effects from the intervention. During a median 38 months of follow-up, the primary end point was experienced by a total of 422 participants (13.7%): 219 participants (14.2%) receiving folic acid/vitamin B12 vs 203 (13.1%) not receiving such treatment (hazard ratio, 1.09; 95% confidence interval, 0.90-1.32; P = .36) and 200 participants (13.0%) receiving vitamin B6 vs 222 (14.3%) not receiving vitamin B6 (hazard ratio, 0.90; 95% confidence interval, 0.74-1.09; P = .28).
Conclusions This trial did not find an effect of treatment with folic acid/vitamin B12 or vitamin B6 on total mortality or cardiovascular events. Our findings do not support the use of B vitamins as secondary prevention in patients with coronary artery disease.
Trial Registration clinicaltrials.gov Identifier: NCT00354081
Author Affiliations: Department of Heart Disease, Haukeland University Hospital (Drs Ebbing, Bleie, Nordrehaug, and Nygård), Sections for Pharmacology (Dr Ueland) and Cardiology (Drs Nordrehaug, Nilsen, Ringdal Pedersen, and Nygård), Institute of Medicine, University of Bergen and Haukeland University Hospital, and Department of Public Health and Primary Health Care, University of Bergen (Dr Vollset), Bergen, Norway; Department of Cardiology, Stavanger University Hospital, Stavanger, Norway (Dr Nilsen); Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (Dr Refsum); and Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, England (Dr Refsum).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
Gian Paolo Rossi, Teresa Maria Seccia, and Achille C. Pessina
JAMA. 2008;300(24):2852.
EXTRACT
| FULL TEXT
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
George Ntaios, Christos Savopoulos, and Apostolos Hatzitolios
JAMA. 2008;300(24):2852-2853.
EXTRACT
| FULL TEXT
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
Johannes Scholl
JAMA. 2008;300(24):2853.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effect of folic acid supplementation on the progression of colorectal aberrant crypt foci
Lindzon et al.
Carcinogenesis 2009;30:1536-1543.
ABSTRACT
| FULL TEXT
Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study
Malarstig et al.
Blood 2009;114:1417-1422.
ABSTRACT
| FULL TEXT
Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus
DANOWSKI et al.
The Journal of Rheumatology 2009;36:1195-1199.
ABSTRACT
| FULL TEXT
Nutrient supplements and cardiovascular disease: a heartbreaking story
Lichtenstein
J. Lipid Res. 2009;50:S429-S433.
ABSTRACT
| FULL TEXT
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
Rossi et al.
JAMA 2008;300:2852-2852.
FULL TEXT
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
Scholl
JAMA 2008;300:2853-2853.
FULL TEXT
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
Ntaios et al.
JAMA 2008;300:2852-2853.
FULL TEXT
No Role for Folic Acid or B Vitamins in Lowering Cardiovascular Risk
Journal Watch Cardiology 2008;2008:5-5.
FULL TEXT
Homocysteine-Lowering Therapy: Another Negative Study
JWatch General 2008;2008:1-1.
FULL TEXT
|
